ABSTRACT
Objectives We sought to determine the sensitivity of high resolution peripheral quantitative computed tomography (HR-pQCT) to detect change and identify erosions in comparison with conventional radiography (CR) in early inflammatory arthritis patients. We also explored which prognostic factors contribute to bone damage assessed by HR-pQCT in the first year of diagnosis.
Methods 46 patients with arthritic symptoms less than one year, and a clinical diagnosis of inflammatory arthritis were prospectively imaged at baseline and 12-months. HR-pQCT scans of the 2nd and 3rd MCP joints and CR of the hands and feet were performed. Joint space width (JSW), total bone mineral density (Tt.BMD), erosion presence and volume were assessed with HR-pQCT. Scan-rescan precision was assessed to define an individual-level least significant change (LSC) criterion. Regression analyses explored prognostic factors for bone damage progression.
Results We observed no significant group-level changes in JSW, Tt.BMD or erosion volume. 20% or fewer joints demonstrated individual-level changes greater than the LSC criterion for mean JSW, Tt.BMD and erosion volume. HR-pQCT detected more erosions than CR in the 2nd and 3rd MCP. Increased symptom duration at diagnosis was associated (p < 0.10) with lower JSW minimum and higher JSW standard deviation.
Conclusions We have demonstrated stability in erosion, bone density and JSW over 12-months in most patients receiving treatment for inflammatory arthritis using a LSC criterion, although patients with longer symptom duration prior to treatment initiation had demonstrable negative effects on JSW estimates. HR-pQCT captures bone damage and progression undetectable by CR in the imaged joints.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Study funding was provided by the University of Calgary. Scott Brunet was supported by the Natural Sciences and Engineering Research Council of Canada.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon reasonable request.